|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Hepatitis B | |||||
| Hepatitis, Viral, Human | |||||
| Liver Diseases | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Hepatitis | |||||
| 3 | More general conditions related to this trial | ||||
| Digestive System Diseases | |||||
| DNA Virus Infections | |||||
| Hepadnaviridae Infections | |||||
| Virus Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| immunoglobulins, intravenous | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Immunoglobulins | |||||
| Rho(D) Immune Globulin | |||||
| 6 | More general drug interventions related to this trial | ||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 7 | Sponsors listed in this trial | ||||
| National Heart, Lung, and Blood Institute (NHLBI) | |||||